EXACT THERAPEUTICS OSLO ,7 August 2023 :EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that the dose escalation part of the ACTIVATE study is completed. This part of the study enrolled 8 patients, with 6 patients eligible for evaluation. The study is conducted at theInstitute of Cancer Research (ICR),Royal Marsden Hospital ,London with ProfessorUdai Banerji as the principal investigator. A presentation of the safety and efficacy findings will be released when the full results are available. The study Trial Monitoring Committee reviewed the safety data from the dose escalation and approved initiation of the dose expansion part of the ACTIVATE study. The dose expansion is designed to determine the dose level for further development of ACT and expand the safety and efficacy data with 12 to 20 patients with metastatic colorectal cancer. All necessary approvals have already been awarded by theUK MHRA, as reported onJuly 31st , and enrolment will now commence. For more information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com About EXACT-Tx EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes. Forward looking statements This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.
Click here for more information
© Oslo Bors ASA, source
